Dashboard E. coli
Repurposing candidates for E. coli
Escherichia coli
Approved medicines with AI-predicted activity ≥40% against E. coli, leaving out medicines that are already antimicrobials. Each is shown with what it is already used for. They are surfaced computationally for further investigation, not as treatments.
- AI-predicted activity ≥40%
- 467
- Existing antimicrobials set aside
- 103
- Needing review
- 28
- Repurposing candidates
- 336
Repurposing candidates for E. coli
AI prediction · nothing measuredAll 336 repurposing candidates for E. coli.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Adefovir DipivoxilExisting use: Chronic hepatitis B virus infection, Hepatitis B virus infection, Viral disease41.4% AI-predicted activityagainst E. coli50+ registered studies
- Butorphanol TartrateExisting use: Drug dependence, Pain41.4% AI-predicted activityagainst E. coli24 registered studies
- OlanzapineExisting use: Agitation, Bipolar disorder, Bipolar I disorder and 5 more41.4% AI-predicted activityagainst E. coli50+ registered studies
- VemurafenibExisting use: Cancer, Cutaneous melanoma, Melanoma and 2 more41.4% AI-predicted activityagainst E. coli50+ registered studies
- Pramipexole DihydrochlorideExisting use: Parkinson disease, Restless legs syndrome41.3% AI-predicted activityagainst E. coli50+ registered studies
- BoceprevirExisting use: Chronic hepatitis C virus infection, Viral disease41.3% AI-predicted activityagainst E. coli50+ registered studies
- Hydroxyzine PamoateExisting use: Anxiety, Anxiety disorder, Neurotic disorder and 3 more41.2% AI-predicted activityagainst E. coli50+ registered studies
- RitonavirExisting use: Chronic hepatitis C virus infection, Hepatitis C virus infection, HIV infection and 2 more41.2% AI-predicted activityagainst E. coli50+ registered studies
- Buspirone HydrochlorideExisting use: Anxiety, Anxiety disorder, Depressive disorder and 1 more41.1% AI-predicted activityagainst E. coli50+ registered studies
- Dextromethorphan PolistirexExisting use: Allergic disease, Common cold, Cough and 4 more41.0% AI-predicted activityagainst E. coli50+ registered studies
- RimexoloneExisting use: Eye inflammation41.0% AI-predicted activityagainst E. coli2 registered studies
- ClevidipineExisting use: Cardiovascular disease41.0% AI-predicted activityagainst E. coli34 registered studies
- Eribulin MesylateExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 3 more41.0% AI-predicted activityagainst E. coli50+ registered studies
- Tripelennamine CitrateExisting use: Allergic disease, Pruritus41.0% AI-predicted activityagainst E. coliNo documented evidence found
- MaravirocExisting use: HIV infection, HIV-1 infection, Viral disease40.9% AI-predicted activityagainst E. coli50+ registered studies
- Lasmiditan SuccinateExisting use: Migraine disorder40.9% AI-predicted activityagainst E. coliNo documented evidence found
- Alfuzosin HydrochlorideExisting use: Benign prostatic hyperplasia40.9% AI-predicted activityagainst E. coli50+ registered studies
- Fluticasone FuroateExisting use: Airway obstruction, Allergic rhinitis, Asthma and 4 more40.8% AI-predicted activityagainst E. coli50+ registered studies
- Gallium Ga-68 GozetotideExisting use: Neuroimaging measurement40.8% AI-predicted activityagainst E. coli50+ registered studies
- Valganciclovir HydrochlorideExisting use: Aids, Cytomegalovirus Retinitis, Retinitis and 1 more40.8% AI-predicted activityagainst E. coli50+ registered studies
- Etoposide PhosphateExisting use: Cancer, Lung cancer, Lung neoplasm and 3 more40.7% AI-predicted activityagainst E. coli50+ registered studies
- Tenofovir Disoproxil FumarateExisting use: Chronic hepatitis B virus infection, Hepatitis B virus infection, HIV infection and 4 more40.7% AI-predicted activityagainst E. coli50+ registered studies
- Seladelpar LysineExisting use: Biliary liver cirrhosis40.7% AI-predicted activityagainst E. coliNo documented evidence found
- Eletriptan HydrobromideExisting use: Migraine disorder40.7% AI-predicted activityagainst E. coli2 registered studies